Patent litigation attorney

Anne Y. Brody

2 tracked appearances — 2 plaintiff · 0 defendant.

Specialty & background

Anne Y. Brody — Patent Litigation Practice Summary

Specialty / focus areas. Anne Y. Brody is Of Counsel in Gibson Dunn & Crutcher's Orange County office and a member of the firm's Intellectual Property and Life Sciences practice groups. A Ph.D. chemist (Caltech) before law school, she concentrates on patent litigation and complex commercial disputes in the pharmaceutical and biotech industries, with experience spanning genetically modified T-cell therapies, biologics, peptide drugs, small molecules, and diagnostics (Gibson Dunn bio). Her tracked docket is entirely Hatch-Waxman / 505(b)(2) pharmaceutical work: she appeared for plaintiff Novartis in Novartis Pharmaceuticals Corp. v. Handa Pharmaceuticals, Inc. (D. Del., pro hac vice) and Novartis Pharmaceuticals Corp. v. HEC Pharm Co., Ltd. et al. (D. Del., of counsel), both enforcing the Gilenya® (fingolimod) dosing-regimen patents (U.S. Patent Nos. 9,187,405 and 10,543,179).

Side preference. Both tracked appearances are plaintiff-side (2-0), representing the brand innovator against generic and 505(b)(2) challengers. Her firm bio also reflects substantial defense work — including defending Agilent in Thermo Fisher Scientific v. Agilent Technologies (D. Del.) and multiple diagnostic-company defendants — so she handles both sides but the tracked matters are brand-side enforcement.

Notable matters. In Novartis v. HEC Pharm, the Delaware district court held the '405 patent valid and infringed after a 2020 bench trial and entered a permanent injunction; the Federal Circuit initially affirmed (Jan. 2022) but a reconstituted panel reversed and found the patent invalid (June 2022), and the Supreme Court denied certiorari (2023) — a follow-on preliminary-injunction-bond appeal was pending at the Federal Circuit in 2024 (No. 24-2194). In Novartis v. Handa, the case resolved by confidential settlement and a consent judgment (Oct. 2022) in which Handa stipulated to validity and infringement. Her bio also cites a consolidated Hatch-Waxman trial win affirmed by the Federal Circuit, and IPR work on protein-vaccine patents.

PTAB / IPR experience. She is registered before the USPTO (Reg. No. 54,612) and has appeared as back-up counsel in PTAB proceedings, including IPR2018-00313 (reissue patent), plus inter partes reviews of vaccine patents per her firm bio — a meaningful but not dominant part of her practice.

Bar / education. California bar (2007); J.D., USC Gould School of Law (2007); Ph.D. chemistry, Caltech (2002); B.S. chemistry with high honors, UC Berkeley (1996). No prior law firm is disclosed in her bio; before Gibson Dunn she worked as a research scientist developing diagnostic tools.

Firms

Roles

  • pro hac vice1
  • of counsel1

Cases (2)